BioMarin Acquiring Amicus — Both Great Companies, Only One Worth Buying Now (NASDAQ:BMRN)

Core Viewpoint - BioMarin Pharmaceutical Inc. is acquiring Amicus Therapeutics, Inc. at a price of $14.50 per share, with the transaction expected to take effect in Q2 2026 [1] Company Overview - BioMarin Pharmaceutical Inc. is involved in the acquisition of Amicus Therapeutics, indicating a strategic move to expand its portfolio [1] - Amicus Therapeutics, Inc. is the target of the acquisition, which may enhance BioMarin's capabilities in the pharmaceutical sector [1]